Dexcom Inc
NASDAQ:DXCM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Encho Co Ltd
TSE:8208
|
JP |
|
EnBW Energie Baden Wuerttemberg AG
XETRA:EBK
|
DE |
|
A2A SpA
OTC:AEMMY
|
IT |
|
YD Bio Ltd
NASDAQ:YDES
|
TW |
Dexcom Inc
Narrow
Economic Moat
Narrow economic moat driven primarily by proprietary sensor IP and data-driven ecosystem, reinforced by switching costs and concentrated market dynamics.
Dexcom Inc
Competitive Advantages
Cloud/mobile data sharing, caregiver/follower features and integrations with pump/health platforms increase product value as more patients and clinical partners adopt the Dexcom ecosystem.
Longitudinal patient glucose datasets, clinical workflows and integrations with insulin delivery and clinician systems create high clinical and behavioral friction for users to switch vendors.
Extensive proprietary sensor and algorithm IP and regulatory-cleared product generations (e.g., G7 15‑day) that protect core sensing technology and support product differentiation and commercial launches.
CGM distribution is highly concentrated with large fixed regulatory and manufacturing barriers, favoring incumbent scale for R&D, production and reimbursement relationships over smaller entrants.
Wide Economic Moat Companies
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
NVIDIA Corp
NVDA
|
$183.91 |
+0.9%
|
$4.5T | Wide |
|
|
|
Apple Inc
AAPL
|
$260.49 |
+2.1%
|
$3.8T | Wide |
|
|
|
Alphabet Inc
GOOGL
|
$318.49 |
-0.2%
|
$3.9T | Wide |
|
|
|
Microsoft Corp
MSFT
|
$373.07 |
+1%
|
$2.8T | Wide |
|
|
|
Amazon.com Inc
AMZN
|
$233.65 |
+1.7%
|
$2.5T | Wide |
|
|
|
Taiwan Semiconductor Manufacturing Co Ltd
2330
|
NT$1 990 |
+2.6%
|
$1.6T | Wide |
|
|
|
Meta Platforms Inc
META
|
$628.39 |
+0.1%
|
$1.6T | Wide |
|
|
|
Broadcom Inc
AVGO
|
$354.91 |
-2%
|
$1.7T | Wide |
|
|
|
Walmart Inc
WMT
|
$129.13 |
+0.6%
|
$1T | Wide |
|
|
|
Eli Lilly and Co
LLY
|
$955.19 |
-1.3%
|
$903B | Wide |
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
AstraZeneca PLC
AZN
|
GBX15 306 |
-0.1%
|
$320.3B | Wide |
|
|
|
Kweichow Moutai Co Ltd
600519
|
¥1 455.39 |
+1.7%
|
$264.8B | Wide |
|
|
|
Novo Nordisk A/S
NOVO B
|
kr242 |
-1.9%
|
$169.5B | Wide |
|
|
|
Zhongji Innolight Co Ltd
300308
|
¥739.14 |
+2.6%
|
$119.3B | Wide |
|
|
|
Advantest Corp
6857
|
¥24 990 |
+7.3%
|
$118.3B | Wide |
|
|
|
Eoptolink Technology Inc Ltd
300502
|
¥519.7 |
+2.7%
|
$75B | Wide |
|
|
|
Disco Corp
6146
|
¥66 890 |
+5.3%
|
$46.9B | Wide |
|
|
G
|
Gold Fields Ltd
GFI
|
Zac80 076 |
-1.5%
|
$44.9B | Wide |
|
|
|
Suzhou TFC Optical Communication Co Ltd
300394
|
¥361.96 |
-4.1%
|
$40.9B | Wide |
|
|
|
GE Healthcare Technologies Inc
GEHC
|
$72.91 |
+0%
|
$33.2B | Wide |
Dexcom Inc
Glance View
Dexcom Inc. emerged as a pioneering force in the realm of continuous glucose monitoring (CGM), redefining the landscape of diabetes management. Founded in 1999, this San Diego-based company disrupted traditional blood glucose monitoring with its innovative technology, allowing individuals to track glucose levels in real-time without frequent finger-pricking. The company’s CGM systems, such as the G6 model, utilize a small sensor inserted beneath the skin that transmits data to a wearable device or smartphone, allowing patients and healthcare providers a comprehensive view of glucose trends. This approach empowers users with critical information for better diabetes management, reducing the likelihood of complications resulting from high or low blood sugar. Dexcom’s revenue generation revolves around the sales of its CGM systems, sensors, and related software services. By selling the initial monitoring devices and disposable sensors that typically need to be replaced every ten days, the company ensures a steady, recurring revenue stream. Furthermore, its integration with healthcare providers and insurers broadens its reach, tapping into a vast network of patients worldwide. Dexcom also collaborates with tech giants to enhance interoperability and data analytics, thereby embedding its solutions in broader digital health ecosystems. As diabetes continues to be a growing global concern, Dexcom’s strategic focus on innovation and strategic partnerships positions it as a leader in the CGM market.
Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.
The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.
Note: This research does not account for survivorship bias. Past performance is not indicative of future results.
Economic Moat